cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.6655223.v1
title: The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study

description: <b>Background</b>: Volanesorsen, an investigational inhibitor of apoC-III synthesis, significantly reduced triglyceride levels in clinical trials in patients with familial chylomicronemia syndrome (FCS), a rare genetic disorder characterized by marked chylomicronemia leading to a spectrum of symptoms, including recurrent abdominal pain and episodes of potentially fatal acute pancreatitis (AP). <b>Objective</b>: To determine the effect of volanesorsen on burden of disease on patients with FCS <b>Methods</b>: ReFOCUS was a retrospective global web-based survey open to patients with FCS who received volanesorsen for ≥3 months in an open-label extension study. The survey included questions about patients’ experiences before and after volanesorsen treatment. <b>Results</b>: Twenty-two respondents had received volanesorsen for a median of 222 days. Volanesorsen significantly reduced the number of symptoms per patient across physical, emotional, and cognitive domains. Significant reductions from baseline were reported for steatorrhea, pancreatic pain, and constant worry about an attack of pain/AP. Respondents reported that volanesorsen improved overall management of symptoms and reduced interference of FCS with work/school responsibilities. Reductions in the negative impact of FCS on personal, social, and professional life were also reported. <b>Conclusions</b>: Treatment with volanesorsen has the potential to reduce disease burden in patients with FCS through modulation of multiple symptom domains.
DOI: 10.6084/m9.figshare.6655028
title: Concerns related to the accurate identification of anterior derangement syndrome in mechanical diagnosis and therapy for low back pain: A case report

description: <b><i>Background:</i></b> In Mechanical Diagnosis and Therapy (MDT), patients with low back pain (LBP) are classified into subgroups to guide a management strategy. A common subgroup where symptoms improve with lumbar extension is labeled posterior derangement syndrome. A less common subgroup where symptoms improve with lumbar flexion is labeled anterior derangement syndrome. <b><i>Case Presentation:</i></b> The patient was a 23-year-old woman with intermittent LBP and discomfort over the left lower extremity was initially diagnosis with posterior derangement syndrome. At the initial and second consultations, postural correction and home exercises with lumbar extension were prescribed. However, at the third consultation, sustained lumbar extension revealed worsening of symptoms and function, which resulted in a revised diagnosis of anterior derangement syndrome. Complete recovery was achieved using exercises with lumbar flexion over 6 weeks. <b><i>Outcomes:</i></b> The patient wore the LUMOback in daily life, which is a wearable device measuring pelvic angle and acceleration, for 1 week before the initial MDT consultation and for 6 weeks until discharge. The posture scores (%) is the proportion of time in a week with neutral pelvic tilt. In this patient, the posture score decreased greater than a minimum detectable change of 11.7% when MDT classification changed to anterior derangement. <b><i>Conclusions</i></b>: This case report indicates the importance of sustained loading to identify the correct derangement syndrome, and follow-up sessions to confirm or reject the initial diagnosis by monitoring symptom and functional changes carefully. Habitual posture may be associated with reduction and aggravation of symptoms.
DOI: 10.6084/m9.figshare.6655028.v1
title: Concerns related to the accurate identification of anterior derangement syndrome in mechanical diagnosis and therapy for low back pain: A case report

description: <b><i>Background:</i></b> In Mechanical Diagnosis and Therapy (MDT), patients with low back pain (LBP) are classified into subgroups to guide a management strategy. A common subgroup where symptoms improve with lumbar extension is labeled posterior derangement syndrome. A less common subgroup where symptoms improve with lumbar flexion is labeled anterior derangement syndrome. <b><i>Case Presentation:</i></b> The patient was a 23-year-old woman with intermittent LBP and discomfort over the left lower extremity was initially diagnosis with posterior derangement syndrome. At the initial and second consultations, postural correction and home exercises with lumbar extension were prescribed. However, at the third consultation, sustained lumbar extension revealed worsening of symptoms and function, which resulted in a revised diagnosis of anterior derangement syndrome. Complete recovery was achieved using exercises with lumbar flexion over 6 weeks. <b><i>Outcomes:</i></b> The patient wore the LUMOback in daily life, which is a wearable device measuring pelvic angle and acceleration, for 1 week before the initial MDT consultation and for 6 weeks until discharge. The posture scores (%) is the proportion of time in a week with neutral pelvic tilt. In this patient, the posture score decreased greater than a minimum detectable change of 11.7% when MDT classification changed to anterior derangement. <b><i>Conclusions</i></b>: This case report indicates the importance of sustained loading to identify the correct derangement syndrome, and follow-up sessions to confirm or reject the initial diagnosis by monitoring symptom and functional changes carefully. Habitual posture may be associated with reduction and aggravation of symptoms.
DOI: 10.6084/m9.figshare.6654956
title: Budesonide with multi-matrix technology as second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands

description: <b>Aims:</b> Budesonide with multi-matrix technology (MMX) is an oral corticosteroid, shown to have high topical activity against ulcerative colitis (UC) while maintaining low systemic bioavailability with few adverse events. The aim of this study was to evaluate the cost-effectiveness of budesonide MMX versus commonly used corticosteroids, in the second-line treatment of active mild-to-moderate UC in the Netherlands. <b>Materials and methods:</b> An eight-state Markov model with an 8 week cycle length captured remission, four distinct therapy stages, hospitalization, possible colectomy and mortality. Remission probability for budesonide MMX was based on the CORE-II study. Population characteristics were derived from the Dutch Inflammatory Bowel Disease South Limburg cohort (<i>n</i> = 598) and included patients with proctitis (39%), left-sided (42%) and extensive disease (19%). Comparators (topical budesonide foam and enema, oral budesonide and prednisolone) were selected based on current Dutch clinical practice. Treatment effects were evaluated by network meta-analysis using a Bayesian framework. Cost-effectiveness analysis was performed over a 5 year time horizon from a societal perspective, with costs, health-state and adverse event utilities derived from published sources. Outcomes were weighted by disease extent distribution and corresponding comparators. <b>Results:</b> Budesonide MMX was associated with comparable quality-adjusted life year (QALY) gain versus foam and oral formulations (+0.01 QALYs) in the total UC population, whilst being cost-saving (EUR 366 per patient). Probabilistic sensitivity analysis evaluated an 86.6% probability of budesonide MMX being dominant (cost-saving with QALY gain) versus these comparators. Exploratory analysis showed similar findings versus prednisolone. <b>Limitations:</b> Differing definitions of trial end-points and remission across trials meant indirect comparison was not ideal. However, in the absence of head-to-head clinical data, these comparisons are reasonable alternatives and currently offer the only comparison of second-line UC treatments. <b>Conclusions:</b> In the present analysis, budesonide MMX was shown to be cost-effective versus comparators in the total UC population, for the second-line treatment of active mild-to-moderate UC in the Netherlands.
DOI: 10.6084/m9.figshare.6654956.v1
title: Budesonide with multi-matrix technology as second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands

description: <b>Aims:</b> Budesonide with multi-matrix technology (MMX) is an oral corticosteroid, shown to have high topical activity against ulcerative colitis (UC) while maintaining low systemic bioavailability with few adverse events. The aim of this study was to evaluate the cost-effectiveness of budesonide MMX versus commonly used corticosteroids, in the second-line treatment of active mild-to-moderate UC in the Netherlands. <b>Materials and methods:</b> An eight-state Markov model with an 8 week cycle length captured remission, four distinct therapy stages, hospitalization, possible colectomy and mortality. Remission probability for budesonide MMX was based on the CORE-II study. Population characteristics were derived from the Dutch Inflammatory Bowel Disease South Limburg cohort (<i>n</i> = 598) and included patients with proctitis (39%), left-sided (42%) and extensive disease (19%). Comparators (topical budesonide foam and enema, oral budesonide and prednisolone) were selected based on current Dutch clinical practice. Treatment effects were evaluated by network meta-analysis using a Bayesian framework. Cost-effectiveness analysis was performed over a 5 year time horizon from a societal perspective, with costs, health-state and adverse event utilities derived from published sources. Outcomes were weighted by disease extent distribution and corresponding comparators. <b>Results:</b> Budesonide MMX was associated with comparable quality-adjusted life year (QALY) gain versus foam and oral formulations (+0.01 QALYs) in the total UC population, whilst being cost-saving (EUR 366 per patient). Probabilistic sensitivity analysis evaluated an 86.6% probability of budesonide MMX being dominant (cost-saving with QALY gain) versus these comparators. Exploratory analysis showed similar findings versus prednisolone. <b>Limitations:</b> Differing definitions of trial end-points and remission across trials meant indirect comparison was not ideal. However, in the absence of head-to-head clinical data, these comparisons are reasonable alternatives and currently offer the only comparison of second-line UC treatments. <b>Conclusions:</b> In the present analysis, budesonide MMX was shown to be cost-effective versus comparators in the total UC population, for the second-line treatment of active mild-to-moderate UC in the Netherlands.
DOI: 10.6084/m9.figshare.6654911
title: Mediterranean waterbird functional diversity and traits

description: These are three datasets. Div.alfa.csv describes functional diversity indexes for wintering and breeding waterbird communities on 11 Mediterranean wetlands from 1990 to 2017. Beta.ano.csv gives taxonomic and functional beta diversity of waterbird wintering and breeding waterbirds among the 11 wetlands and its turnover and nestedness components for each year, from 1990 to 2017. Traits.csv is the functional trait matrix for the waterbird species found in these wetlands for all the years.
DOI: 10.6084/m9.figshare.6654911.v1
title: Mediterranean waterbird functional diversity and traits

description: These are three datasets. Div.alfa.csv describes functional diversity indexes for wintering and breeding waterbird communities on 11 Mediterranean wetlands from 1990 to 2017. Beta.ano.csv gives taxonomic and functional beta diversity of waterbird wintering and breeding waterbirds among the 11 wetlands and its turnover and nestedness components for each year, from 1990 to 2017. Traits.csv is the functional trait matrix for the waterbird species found in these wetlands for all the years.
DOI: 10.6084/m9.figshare.6654821
title: DATABASE HEALTHCARE UTILIZATION AND HEALTH BEHAVIORS PROSPECTIVE APPROACH

description: Follow-up study, Health workers cohort study, prospective association of health behaviors and health services utilization
DOI: 10.6084/m9.figshare.6654821.v1
title: DATABASE HEALTHCARE UTILIZATION AND HEALTH BEHAVIORS PROSPECTIVE APPROACH

description: Follow-up study, Health workers cohort study, prospective association of health behaviors and health services utilization
DOI: 10.6084/m9.figshare.6654794
title: Evaluating the effectiveness of systemic corticosteroids to mitigate relapse in children assessed and treated for acute asthma: A network meta-analysis

description: <i>Objective</i>: The objective of this systematic review was to explore the effectiveness of various systemic corticosteroid (SCS) regimens to mitigate relapse in children with asthma discharged from an acute care setting. <i>Data Sources</i>: Medline, EMBASE, Global Health, International Pharmaceutical Abstracts, EMB ALL, CINAHL, SCOPUS, Proquest Dissertations and Theses Global, and LILACS were searched using controlled vocabulary and key words. Additional citations were searched via clinical trial registries, Google Scholar, bibliographies, a SCOPUS forward search of a sentinel paper, and hand searching conference abstracts. <i>Study Selection</i>: No limitations based on language, publication status, or year of publication were applied. Two independent reviewers searched to identify randomized controlled trials comparing the effectiveness of SCS regimens to prevent relapse in children following treatment for acute asthma. <i>Results</i>: Fifteen studies were included. In 3 studies comparing SCS to placebo, asthma relapse was significantly reduced (RR = 0.10; 95% CI: 0.01, 0.77; <i>I</i><sup>2</sup> = 0%). A network analysis identified a significant reduction in relapse in children treated with intramuscular corticosteroids (OR = 0.038; 95% CrI: 0.001, 0.397), short-course oral prednisone (OR = 0.054; 95% CrI: 0.002, 0.451), and oral dexamethasone (OR = 0.071; 95% CrI: 0.002, 0.733) compared to placebo. <i>Conclusion</i>: This review found evidence that SCS reduces relapse in children following treatment for acute asthma, albeit based on a limited number of studies. Additional studies are required to assess the differential effect of SCS doses and treatment duration to prevent relapse in children following discharge for acute asthma.
DOI: 10.6084/m9.figshare.6654794.v1
title: Evaluating the effectiveness of systemic corticosteroids to mitigate relapse in children assessed and treated for acute asthma: A network meta-analysis

description: <i>Objective</i>: The objective of this systematic review was to explore the effectiveness of various systemic corticosteroid (SCS) regimens to mitigate relapse in children with asthma discharged from an acute care setting. <i>Data Sources</i>: Medline, EMBASE, Global Health, International Pharmaceutical Abstracts, EMB ALL, CINAHL, SCOPUS, Proquest Dissertations and Theses Global, and LILACS were searched using controlled vocabulary and key words. Additional citations were searched via clinical trial registries, Google Scholar, bibliographies, a SCOPUS forward search of a sentinel paper, and hand searching conference abstracts. <i>Study Selection</i>: No limitations based on language, publication status, or year of publication were applied. Two independent reviewers searched to identify randomized controlled trials comparing the effectiveness of SCS regimens to prevent relapse in children following treatment for acute asthma. <i>Results</i>: Fifteen studies were included. In 3 studies comparing SCS to placebo, asthma relapse was significantly reduced (RR = 0.10; 95% CI: 0.01, 0.77; <i>I</i><sup>2</sup> = 0%). A network analysis identified a significant reduction in relapse in children treated with intramuscular corticosteroids (OR = 0.038; 95% CrI: 0.001, 0.397), short-course oral prednisone (OR = 0.054; 95% CrI: 0.002, 0.451), and oral dexamethasone (OR = 0.071; 95% CrI: 0.002, 0.733) compared to placebo. <i>Conclusion</i>: This review found evidence that SCS reduces relapse in children following treatment for acute asthma, albeit based on a limited number of studies. Additional studies are required to assess the differential effect of SCS doses and treatment duration to prevent relapse in children following discharge for acute asthma.
DOI: 10.6084/m9.figshare.6654287
title: 16S sequence data from Ruiz Gonzalez et al. FEMS Microbiology Ecology article

description: Bacterial 16S sequence data for bacterial communities sampled at the Montreal IDENT experiment in Ste-Anne de Bellevue.<br>Data collection procedures are described in the paper "Soils associated to different tree communities do not elicit predictable responses in lake bacterial community structure and function" by Clara Ruiz Gonzalez et al., in press at FEMS Microbiology Ecology.<br><br>The sequences are in the fasta format, they have been adapter-trimmed, assembled and quality filtered as described in the article.
DOI: 10.6084/m9.figshare.6654287.v1
title: 16S sequence data from Ruiz Gonzalez et al. FEMS Microbiology Ecology article

description: Bacterial 16S sequence data for bacterial communities sampled at the Montreal IDENT experiment in Ste-Anne de Bellevue.<br>Data collection procedures are described in the paper "Soils associated to different tree communities do not elicit predictable responses in lake bacterial community structure and function" by Clara Ruiz Gonzalez et al., in press at FEMS Microbiology Ecology.<br><br>The sequences are in the fasta format, they have been adapter-trimmed, assembled and quality filtered as described in the article.
DOI: 10.6084/m9.figshare.6653645
title: Molecular dynamics and quantum chemistry-based approaches to identify isoform selective HDAC2 inhibitor – a novel target to prevent Alzheimer’s disease

description: Histone deacetylase 2 (HDAC2) is an emerging target of Alzheimer’s disease. Four featured pharmacophore model (ADRR) with one H-bond acceptor (A), one H-bond donor (D), and two aromatic rings (R) was generated using experimentally reported compounds, ((E-5[3-benzenesulfonamido) phenyl]-N-hydroxypent-2-en-4-ynamide)) and (N’-hydroxy-N-phenyloctanediamide) with IC<sub>50</sub> values of 0.16 ± 0.11 nM and 62 ± 0.15 nM, respectively. Quantum Polarized Ligand Docking and Binding Free Energy calculation was performed for the top three identified leads RH01652, JFD02573, and HTS00800 from HitFinder database. RH01652 (methyl 2-[({5-[(benzoylamino) methyl]-2-thienyl} sulfonyl) amino]-3-(1H-indol-3-yl) propanoate) with docking score (−12.62 kcal/mol) and binding free energy (−75.27 kcal/mol), shows good binding affinity. RH01652 interacts with Gly154, His183, Glu208, and Phe210 with four H-bonds and stabilized by π–π interactions with His146, Tyr209, and Phe210. DFT studies at B3LYP level with 6-31G* basis set for the lead RH01652 reveals low band gap/Δ<i>E</i> (<i>E</i><sub>HOMO</sub>–<i>E</i><sub>LUMO</sub>) of −0.16 eV, which illustrates good reactivity of the lead. MD simulation studies (40 ns) was performed to confirm the stability of lead binding. Comparative molecular docking studies of the lead RH01652 with class I HDACs (HDAC1, HDAC2, HDAC3, and HDAC8) shows higher binding affinity towards HDAC2. Thus, lead RH01652 could serve as template to design novel and potent inhibitor of HDAC2.
DOI: 10.6084/m9.figshare.6653645.v1
title: Molecular dynamics and quantum chemistry-based approaches to identify isoform selective HDAC2 inhibitor – a novel target to prevent Alzheimer’s disease

description: Histone deacetylase 2 (HDAC2) is an emerging target of Alzheimer’s disease. Four featured pharmacophore model (ADRR) with one H-bond acceptor (A), one H-bond donor (D), and two aromatic rings (R) was generated using experimentally reported compounds, ((E-5[3-benzenesulfonamido) phenyl]-N-hydroxypent-2-en-4-ynamide)) and (N’-hydroxy-N-phenyloctanediamide) with IC<sub>50</sub> values of 0.16 ± 0.11 nM and 62 ± 0.15 nM, respectively. Quantum Polarized Ligand Docking and Binding Free Energy calculation was performed for the top three identified leads RH01652, JFD02573, and HTS00800 from HitFinder database. RH01652 (methyl 2-[({5-[(benzoylamino) methyl]-2-thienyl} sulfonyl) amino]-3-(1H-indol-3-yl) propanoate) with docking score (−12.62 kcal/mol) and binding free energy (−75.27 kcal/mol), shows good binding affinity. RH01652 interacts with Gly154, His183, Glu208, and Phe210 with four H-bonds and stabilized by π–π interactions with His146, Tyr209, and Phe210. DFT studies at B3LYP level with 6-31G* basis set for the lead RH01652 reveals low band gap/Δ<i>E</i> (<i>E</i><sub>HOMO</sub>–<i>E</i><sub>LUMO</sub>) of −0.16 eV, which illustrates good reactivity of the lead. MD simulation studies (40 ns) was performed to confirm the stability of lead binding. Comparative molecular docking studies of the lead RH01652 with class I HDACs (HDAC1, HDAC2, HDAC3, and HDAC8) shows higher binding affinity towards HDAC2. Thus, lead RH01652 could serve as template to design novel and potent inhibitor of HDAC2.
DOI: 10.6084/m9.figshare.6653504
title: Mohammad SCFprom-1_Supplement_6.22.2018.pdf

description: Supplemental materials for the paper "Initiation of meiotic development is controlled by three posttranscriptional pathways in C. elegans"
DOI: 10.6084/m9.figshare.6653504.v2
title: Mohammad SCFprom-1_Supplement_6.22.2018.pdf

description: Supplemental materials for the paper "Initiation of meiotic development is controlled by three posttranscriptional pathways in C. elegans"
DOI: 10.5519/qd.hmv343mg
title: Query on the Natural History Museum Data Portal (data.nhm.ac.uk) (1 records)
DOI: 10.6084/m9.figshare.6653417
title: Domain transfer convolutional attribute embedding

description: In this paper, we study the problem of transfer learning with the attribute data. In the transfer learning problem, we want to leverage the data of the auxiliary and the target domains to build an effective model for the classification problem in the target domain. Meanwhile, the attributes are naturally stable cross different domains. This strongly motives us to learn effective domain transfer attribute representations. To this end, we proposed to embed the attributes of the data to a common space using the powerful convolutional neural network (CNN) model. The convolutional representations of the data points are mapped to the corresponding attributes so that they can be effective embedding of the attributes. We also represent the data of different domains by a domain-independent CNN, ant a domain-specific CNN and combine their outputs with the attribute embedding to build the classification model. An joint learning framework is constructed to minimise the classification errors, the attribute mapping error, the mismatching of the domain-independent representations cross different domains, and to encourage the neighbourhood smoothness of representations in the target domain. The minimisation problem is solved by an iterative algorithm based on gradient descent. Experiments over benchmark data-sets of person re-identification, bankruptcy prediction and spam email detection show the effectiveness of the proposed method.